Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05676034 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AMX0035 in Adult Patients With Wolfram Syndrome

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints revised (2)
    • Study completion date: Dec 31, 2026 to May 31, 2028
    v8
  2. Primary endpoints revised (2)
    • Study completion date: Jan 30, 2026 to Dec 31, 2026
    • Secondary endpoints: 4 to 5
    v7
  3. Primary completion date changed from estimate of Jul 17, 2024 to Jul 23, 2024v6
  4. Trial status: Recruiting to Active, Not Recruitingv5 Show 4 more changesShow less
    • Primary completion date: Nov 2024 to Jul 17, 2024
    • Study completion date: Dec 2024 to Jan 30, 2026
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised
  5. Primary completion date: Feb 2024 to Nov 2024
    • Study completion date: Feb 2024 to Dec 2024
    • Secondary endpoints: details revised at 4 of 4 entries
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date changed from estimate of Mar 2023 to Mar 3, 2023
    • Site contact updated
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Feb 2023 to Mar 2023
    • Study title shortened, about 9 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.
Trial Details
NCT Number NCT05676034
Lead Sponsor Amylyx Pharmaceuticals Inc.
Conditions
(from sponsor)		 Wolfram Syndrome
Related terms Wolfram Syndrome
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov